Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of KAD-1229 as combination
therapy with insulin for 16 weeks and up to 52 weeks administration in patients with type 2
Diabetes Mellitus who show inadequate glycemic control with diet, and insulin monotherapy, or
insulin and oral hypoglycemic agent.